nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—Dissociation—Varenicline—nicotine dependence	0.06	0.086	CcSEcCtD
Naratriptan—Panic reaction—Varenicline—nicotine dependence	0.0434	0.0621	CcSEcCtD
Naratriptan—Rhinitis allergic—Varenicline—nicotine dependence	0.0384	0.0549	CcSEcCtD
Naratriptan—Pleurisy—Varenicline—nicotine dependence	0.0357	0.0511	CcSEcCtD
Naratriptan—Polydipsia—Varenicline—nicotine dependence	0.0281	0.0402	CcSEcCtD
Naratriptan—Transient ischaemic attack—Varenicline—nicotine dependence	0.0173	0.0247	CcSEcCtD
Naratriptan—Balance disorder—Varenicline—nicotine dependence	0.0159	0.0228	CcSEcCtD
Naratriptan—Hostility—Varenicline—nicotine dependence	0.0157	0.0225	CcSEcCtD
Naratriptan—Gastric ulcer—Varenicline—nicotine dependence	0.015	0.0215	CcSEcCtD
Naratriptan—Electrocardiogram abnormal—Varenicline—nicotine dependence	0.0133	0.019	CcSEcCtD
Naratriptan—Hyperlipidaemia—Varenicline—nicotine dependence	0.0121	0.0173	CcSEcCtD
Naratriptan—Scotoma—Varenicline—nicotine dependence	0.0115	0.0164	CcSEcCtD
Naratriptan—Glycosuria—Varenicline—nicotine dependence	0.0107	0.0154	CcSEcCtD
Naratriptan—Aggression—Varenicline—nicotine dependence	0.00991	0.0142	CcSEcCtD
Naratriptan—Sumatriptan—DRD2—nicotine dependence	0.00989	1	CrCbGaD
Naratriptan—Ventricular extrasystoles—Varenicline—nicotine dependence	0.00964	0.0138	CcSEcCtD
Naratriptan—HTR1F—brain—nicotine dependence	0.00953	0.131	CbGeAlD
Naratriptan—HTR1F—Monoamine GPCRs—DRD2—nicotine dependence	0.00943	0.0431	CbGpPWpGaD
Naratriptan—Coordination abnormal—Varenicline—nicotine dependence	0.00887	0.0127	CcSEcCtD
Naratriptan—Blood pressure increased—Varenicline—nicotine dependence	0.00871	0.0125	CcSEcCtD
Naratriptan—Photophobia—Varenicline—nicotine dependence	0.00818	0.0117	CcSEcCtD
Naratriptan—Dry eye—Varenicline—nicotine dependence	0.00804	0.0115	CcSEcCtD
Naratriptan—Oesophagitis—Varenicline—nicotine dependence	0.00796	0.0114	CcSEcCtD
Naratriptan—HTR1B—cardiovascular system—nicotine dependence	0.00796	0.109	CbGeAlD
Naratriptan—HTR1F—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00793	0.0362	CbGpPWpGaD
Naratriptan—Urine output increased—Varenicline—nicotine dependence	0.00787	0.0113	CcSEcCtD
Naratriptan—HTR1D—cardiovascular system—nicotine dependence	0.0077	0.106	CbGeAlD
Naratriptan—Sleep disorder—Varenicline—nicotine dependence	0.0073	0.0105	CcSEcCtD
Naratriptan—Polyuria—Varenicline—nicotine dependence	0.0072	0.0103	CcSEcCtD
Naratriptan—Eye pain—Varenicline—nicotine dependence	0.007	0.01	CcSEcCtD
Naratriptan—Libido decreased—Varenicline—nicotine dependence	0.00682	0.00976	CcSEcCtD
Naratriptan—Atrial fibrillation—Varenicline—nicotine dependence	0.00667	0.00955	CcSEcCtD
Naratriptan—Thirst—Varenicline—nicotine dependence	0.00664	0.00951	CcSEcCtD
Naratriptan—Cerebrovascular accident—Varenicline—nicotine dependence	0.00645	0.00924	CcSEcCtD
Naratriptan—HTR1F—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00643	0.0294	CbGpPWpGaD
Naratriptan—HTR1A—cardiovascular system—nicotine dependence	0.00642	0.088	CbGeAlD
Naratriptan—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00627	0.00898	CcSEcCtD
Naratriptan—Migraine—Varenicline—nicotine dependence	0.00622	0.00891	CcSEcCtD
Naratriptan—HTR1B—midbrain—nicotine dependence	0.00621	0.0851	CbGeAlD
Naratriptan—HTR1D—Monoamine GPCRs—DRD2—nicotine dependence	0.00603	0.0276	CbGpPWpGaD
Naratriptan—HTR1D—midbrain—nicotine dependence	0.00602	0.0824	CbGeAlD
Naratriptan—HTR1B—Monoamine GPCRs—DRD2—nicotine dependence	0.0059	0.027	CbGpPWpGaD
Naratriptan—MAOA—cardiovascular system—nicotine dependence	0.00587	0.0804	CbGeAlD
Naratriptan—Liver function test abnormal—Varenicline—nicotine dependence	0.00584	0.00836	CcSEcCtD
Naratriptan—Dry skin—Varenicline—nicotine dependence	0.00579	0.0083	CcSEcCtD
Naratriptan—Cramp muscle—Varenicline—nicotine dependence	0.00569	0.00815	CcSEcCtD
Naratriptan—MAOA—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00562	0.0257	CbGpPWpGaD
Naratriptan—Gastritis—Varenicline—nicotine dependence	0.00559	0.00801	CcSEcCtD
Naratriptan—Asthma—Varenicline—nicotine dependence	0.00546	0.00782	CcSEcCtD
Naratriptan—Angina pectoris—Varenicline—nicotine dependence	0.00532	0.00762	CcSEcCtD
Naratriptan—Bronchitis—Varenicline—nicotine dependence	0.00525	0.00752	CcSEcCtD
Naratriptan—Abdominal discomfort—Varenicline—nicotine dependence	0.00524	0.0075	CcSEcCtD
Naratriptan—HTR1D—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00507	0.0232	CbGpPWpGaD
Naratriptan—Pollakiuria—Varenicline—nicotine dependence	0.00505	0.00723	CcSEcCtD
Naratriptan—HTR1A—midbrain—nicotine dependence	0.00501	0.0687	CbGeAlD
Naratriptan—Photosensitivity reaction—Varenicline—nicotine dependence	0.00499	0.00714	CcSEcCtD
Naratriptan—HTR1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00496	0.0227	CbGpPWpGaD
Naratriptan—Hyperglycaemia—Varenicline—nicotine dependence	0.00493	0.00706	CcSEcCtD
Naratriptan—Depression—Varenicline—nicotine dependence	0.00486	0.00696	CcSEcCtD
Naratriptan—Acute coronary syndrome—Varenicline—nicotine dependence	0.0048	0.00688	CcSEcCtD
Naratriptan—Myocardial infarction—Varenicline—nicotine dependence	0.00478	0.00684	CcSEcCtD
Naratriptan—MAOA—midbrain—nicotine dependence	0.00458	0.0627	CbGeAlD
Naratriptan—Sinusitis—Varenicline—nicotine dependence	0.00457	0.00654	CcSEcCtD
Naratriptan—HTR1A—Monoamine GPCRs—DRD2—nicotine dependence	0.0045	0.0206	CbGpPWpGaD
Naratriptan—Bradycardia—Varenicline—nicotine dependence	0.00445	0.00638	CcSEcCtD
Naratriptan—Hypoaesthesia—Varenicline—nicotine dependence	0.00435	0.00623	CcSEcCtD
Naratriptan—Hallucination—Varenicline—nicotine dependence	0.00435	0.00623	CcSEcCtD
Naratriptan—HTR1D—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00411	0.0188	CbGpPWpGaD
Naratriptan—Tinnitus—Varenicline—nicotine dependence	0.00408	0.00584	CcSEcCtD
Naratriptan—Cardiac disorder—Varenicline—nicotine dependence	0.00406	0.00581	CcSEcCtD
Naratriptan—HTR1B—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00403	0.0184	CbGpPWpGaD
Naratriptan—Angiopathy—Varenicline—nicotine dependence	0.00397	0.00568	CcSEcCtD
Naratriptan—Immune system disorder—Varenicline—nicotine dependence	0.00395	0.00566	CcSEcCtD
Naratriptan—Chills—Varenicline—nicotine dependence	0.00392	0.00562	CcSEcCtD
Naratriptan—Arrhythmia—Varenicline—nicotine dependence	0.00391	0.00559	CcSEcCtD
Naratriptan—HTR1B—brain—nicotine dependence	0.0039	0.0535	CbGeAlD
Naratriptan—HTR1F—GPCR ligand binding—TAS2R16—nicotine dependence	0.0039	0.0178	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00386	0.0176	CbGpPWpGaD
Naratriptan—Erythema—Varenicline—nicotine dependence	0.00381	0.00545	CcSEcCtD
Naratriptan—HTR1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00378	0.0173	CbGpPWpGaD
Naratriptan—HTR1D—brain—nicotine dependence	0.00378	0.0518	CbGeAlD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00366	0.0167	CbGpPWpGaD
Naratriptan—Muscle spasms—Varenicline—nicotine dependence	0.00366	0.00524	CcSEcCtD
Naratriptan—Vision blurred—Varenicline—nicotine dependence	0.00359	0.00514	CcSEcCtD
Naratriptan—Tremor—Varenicline—nicotine dependence	0.00357	0.00511	CcSEcCtD
Naratriptan—Ill-defined disorder—Varenicline—nicotine dependence	0.00353	0.00506	CcSEcCtD
Naratriptan—Anaemia—Varenicline—nicotine dependence	0.00352	0.00504	CcSEcCtD
Naratriptan—Agitation—Varenicline—nicotine dependence	0.0035	0.00501	CcSEcCtD
Naratriptan—Malaise—Varenicline—nicotine dependence	0.00343	0.00492	CcSEcCtD
Naratriptan—Vertigo—Varenicline—nicotine dependence	0.00342	0.0049	CcSEcCtD
Naratriptan—Syncope—Varenicline—nicotine dependence	0.00341	0.00489	CcSEcCtD
Naratriptan—Palpitations—Varenicline—nicotine dependence	0.00336	0.00482	CcSEcCtD
Naratriptan—Loss of consciousness—Varenicline—nicotine dependence	0.00335	0.00479	CcSEcCtD
Naratriptan—Cough—Varenicline—nicotine dependence	0.00332	0.00476	CcSEcCtD
Naratriptan—Convulsion—Varenicline—nicotine dependence	0.0033	0.00472	CcSEcCtD
Naratriptan—Arthralgia—Varenicline—nicotine dependence	0.00324	0.00464	CcSEcCtD
Naratriptan—Myalgia—Varenicline—nicotine dependence	0.00324	0.00464	CcSEcCtD
Naratriptan—Anxiety—Varenicline—nicotine dependence	0.00323	0.00463	CcSEcCtD
Naratriptan—Discomfort—Varenicline—nicotine dependence	0.0032	0.00459	CcSEcCtD
Naratriptan—Dry mouth—Varenicline—nicotine dependence	0.00317	0.00454	CcSEcCtD
Naratriptan—HTR1A—brain—nicotine dependence	0.00315	0.0432	CbGeAlD
Naratriptan—Oedema—Varenicline—nicotine dependence	0.00311	0.00445	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.0031	0.0141	CbGpPWpGaD
Naratriptan—Infection—Varenicline—nicotine dependence	0.00309	0.00442	CcSEcCtD
Naratriptan—HTR1A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00307	0.014	CbGpPWpGaD
Naratriptan—Shock—Varenicline—nicotine dependence	0.00306	0.00438	CcSEcCtD
Naratriptan—Nervous system disorder—Varenicline—nicotine dependence	0.00305	0.00436	CcSEcCtD
Naratriptan—Thrombocytopenia—Varenicline—nicotine dependence	0.00304	0.00436	CcSEcCtD
Naratriptan—Skin disorder—Varenicline—nicotine dependence	0.00302	0.00432	CcSEcCtD
Naratriptan—Hyperhidrosis—Varenicline—nicotine dependence	0.003	0.0043	CcSEcCtD
Naratriptan—MAOA—Biological oxidations—CYP2A7—nicotine dependence	0.00299	0.0136	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—CHRNB3—nicotine dependence	0.00296	0.0135	CbGpPWpGaD
Naratriptan—Hypotension—Varenicline—nicotine dependence	0.0029	0.00416	CcSEcCtD
Naratriptan—MAOA—brain—nicotine dependence	0.00288	0.0394	CbGeAlD
Naratriptan—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00283	0.00405	CcSEcCtD
Naratriptan—MAOA—Neuronal System—CHRNA6—nicotine dependence	0.0028	0.0128	CbGpPWpGaD
Naratriptan—Dyspnoea—Varenicline—nicotine dependence	0.00277	0.00397	CcSEcCtD
Naratriptan—Somnolence—Varenicline—nicotine dependence	0.00276	0.00396	CcSEcCtD
Naratriptan—HTR1F—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00271	0.0124	CbGpPWpGaD
Naratriptan—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00268	0.00384	CcSEcCtD
Naratriptan—Fatigue—Varenicline—nicotine dependence	0.00268	0.00384	CcSEcCtD
Naratriptan—Constipation—Varenicline—nicotine dependence	0.00266	0.0038	CcSEcCtD
Naratriptan—Pain—Varenicline—nicotine dependence	0.00266	0.0038	CcSEcCtD
Naratriptan—MAOA—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00265	0.0121	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00263	0.012	CbGpPWpGaD
Naratriptan—Feeling abnormal—Varenicline—nicotine dependence	0.00256	0.00367	CcSEcCtD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00254	0.0116	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00252	0.0115	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—TAS2R16—nicotine dependence	0.00249	0.0114	CbGpPWpGaD
Naratriptan—Urticaria—Varenicline—nicotine dependence	0.00247	0.00353	CcSEcCtD
Naratriptan—Body temperature increased—Varenicline—nicotine dependence	0.00246	0.00352	CcSEcCtD
Naratriptan—HTR1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00244	0.0111	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00236	0.0108	CbGpPWpGaD
Naratriptan—Hypersensitivity—Varenicline—nicotine dependence	0.00229	0.00328	CcSEcCtD
Naratriptan—Asthenia—Varenicline—nicotine dependence	0.00223	0.00319	CcSEcCtD
Naratriptan—HTR1F—GPCR downstream signaling—TAS2R16—nicotine dependence	0.0022	0.0101	CbGpPWpGaD
Naratriptan—Pruritus—Varenicline—nicotine dependence	0.0022	0.00315	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00216	0.00985	CbGpPWpGaD
Naratriptan—Diarrhoea—Varenicline—nicotine dependence	0.00213	0.00304	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00207	0.00944	CbGpPWpGaD
Naratriptan—Dizziness—Varenicline—nicotine dependence	0.00205	0.00294	CcSEcCtD
Naratriptan—MAOA—Neuronal System—GABRA4—nicotine dependence	0.00203	0.00927	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—TAS2R16—nicotine dependence	0.002	0.00914	CbGpPWpGaD
Naratriptan—Vomiting—Varenicline—nicotine dependence	0.00198	0.00283	CcSEcCtD
Naratriptan—HTR1F—G alpha (i) signalling events—DRD2—nicotine dependence	0.00196	0.00896	CbGpPWpGaD
Naratriptan—Rash—Varenicline—nicotine dependence	0.00196	0.00281	CcSEcCtD
Naratriptan—Dermatitis—Varenicline—nicotine dependence	0.00196	0.0028	CcSEcCtD
Naratriptan—Headache—Varenicline—nicotine dependence	0.00195	0.00279	CcSEcCtD
Naratriptan—MAOA—Neuronal System—CHRNB4—nicotine dependence	0.00194	0.00888	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00192	0.00879	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00188	0.00857	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00186	0.00849	CbGpPWpGaD
Naratriptan—Nausea—Varenicline—nicotine dependence	0.00185	0.00264	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00182	0.00832	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—CHRNA5—nicotine dependence	0.00181	0.00826	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00176	0.00802	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00173	0.00793	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—FGD1—nicotine dependence	0.00173	0.00789	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.0017	0.00776	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00169	0.00774	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—OPRM1—nicotine dependence	0.00164	0.0075	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00161	0.00736	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00159	0.00729	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00158	0.0072	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—FGD1—nicotine dependence	0.00157	0.00717	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00156	0.00712	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.00154	0.00703	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—CHRNA3—nicotine dependence	0.00147	0.00673	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00141	0.00643	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00138	0.0063	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00138	0.0063	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00135	0.00617	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—CHRNB2—nicotine dependence	0.0013	0.00593	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00129	0.00591	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.00128	0.00584	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—DRD2—nicotine dependence	0.00125	0.00573	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00125	0.00572	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—DRD2—nicotine dependence	0.00123	0.00561	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.0012	0.00549	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD2—nicotine dependence	0.00119	0.00543	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TAS2R16—nicotine dependence	0.00118	0.0054	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—CHRNA4—nicotine dependence	0.00118	0.00538	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00116	0.00532	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00114	0.00521	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—FGD1—nicotine dependence	0.0011	0.00505	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—FGD1—nicotine dependence	0.00108	0.00494	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—OPRM1—nicotine dependence	0.00105	0.0048	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00105	0.0048	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00103	0.0047	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—OPRM1—nicotine dependence	0.00103	0.0047	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—FGD1—nicotine dependence	0.001	0.00458	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000997	0.00456	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—FGD1—nicotine dependence	0.000982	0.00449	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000976	0.00446	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000954	0.00436	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—DRD2—nicotine dependence	0.000935	0.00427	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—OPRM1—nicotine dependence	0.000928	0.00424	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—FGD1—nicotine dependence	0.000927	0.00423	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000868	0.00397	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—OPRM1—nicotine dependence	0.000843	0.00385	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000824	0.00377	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AKR1B10—nicotine dependence	0.000819	0.00374	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000783	0.00358	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD2—nicotine dependence	0.000759	0.00347	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TAS2R16—nicotine dependence	0.000755	0.00345	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—FGD1—nicotine dependence	0.000748	0.00342	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000744	0.0034	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD2—nicotine dependence	0.000743	0.0034	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000739	0.00338	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD2—nicotine dependence	0.000671	0.00307	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD2—nicotine dependence	0.000609	0.00278	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—OPRM1—nicotine dependence	0.000593	0.00271	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FGD1—nicotine dependence	0.000593	0.00271	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000581	0.00266	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGD1—nicotine dependence	0.00058	0.00265	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—WASF2—nicotine dependence	0.000577	0.00264	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD2—nicotine dependence	0.000566	0.00259	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000563	0.00257	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—WASF1—nicotine dependence	0.000553	0.00253	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—OPRM1—nicotine dependence	0.000539	0.00246	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000528	0.00241	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AKR1B10—nicotine dependence	0.000523	0.00239	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000513	0.00234	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CYP2A7—nicotine dependence	0.000511	0.00233	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—OPRM1—nicotine dependence	0.000498	0.00228	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000443	0.00202	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGD1—nicotine dependence	0.000442	0.00202	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD2—nicotine dependence	0.000429	0.00196	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD2—nicotine dependence	0.00042	0.00192	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—OPRM1—nicotine dependence	0.000402	0.00184	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKR1B10—nicotine dependence	0.00039	0.00178	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD2—nicotine dependence	0.00039	0.00178	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD2—nicotine dependence	0.000381	0.00174	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—WASF2—nicotine dependence	0.000369	0.00169	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—WASF2—nicotine dependence	0.000361	0.00165	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD2—nicotine dependence	0.00036	0.00164	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—WASF1—nicotine dependence	0.000354	0.00162	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—WASF1—nicotine dependence	0.000346	0.00158	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD2—nicotine dependence	0.00032	0.00146	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—OPRM1—nicotine dependence	0.000318	0.00145	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—OPRM1—nicotine dependence	0.000312	0.00142	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD2—nicotine dependence	0.000291	0.00133	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—WASF2—nicotine dependence	0.000275	0.00126	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—WASF1—nicotine dependence	0.000264	0.00121	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—OPRM1—nicotine dependence	0.000237	0.00109	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD2—nicotine dependence	0.00023	0.00105	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD2—nicotine dependence	0.000225	0.00103	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD2—nicotine dependence	0.000172	0.000785	CbGpPWpGaD
